The emergence of liquid biopsies and non-invasive progression monitoring has resulted in the development of many new cell free DNA (cfDNA) assays. As a result, liquid biopsies are becoming increasingly popular in cancer research.
Investigate their potential impact in the clinic and how current technologies can help us keep pushing the boundaries of precision medicine:
Horizon has developed Reference Standards to support the advancement and continued evaluation of cfDNA workflows across a range of platforms including NGS, ddPCR and qPCR. These high-throughput platforms give researchers greater power when profiling cfDNA samples, however further consideration must be given to sample variability, platform bias, and potential failure to detect biomarkers.
As a result, it is important to have an independent assay control to enable researchers to prove the performance - including sensitivity, specificity, and accuracy of their cell free DNA assays and platforms. Horizon's Reference Standards have been developed in response to this need.
These standards are manufactured from engineered human cancer cell lines, providing a consistent and renewable resource for cell free DNA workflow evaluation.
Our cfDNA Reference Standards are available in several blends to address specific assay challenges including assessing assay specificity, challenging the limit of detection and confirming structural variant detection in cell free DNA workflows.
Still have some questions?
See if the answers are in our list of frequently asked questions about our cell free DNA Reference Standards
Recommended application notes:
Analysis of circulating free DNA at a 1% variant allele fraction using the GeneReader NGS System
Allelic frequency measurement of Multiplex 1 cfDNA Reference Standard Set using Droplet Digital PCR, Ion Torrent and MiSeq
Alternatively, contact our technical team for expert advice: